What is Scilex Holding Company's market cap?

Scilex Holding Company (SCLX) has a market capitalization of $49.4M and trades on NASDAQ.

What is Scilex Holding Company's revenue and profitability?

Scilex Holding Company generated $33.9M in trailing twelve-month revenue with a net loss of $393.6M, representing a net margin of -1162.4%. Gross margin stands at 59.7%. These figures are based on the Q1 2026 filing.

Who are Scilex Holding Company's competitors?

Scilex Holding Company's key competitors include Viatris Inc., Collegium Pharmaceutical, Inc., Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Scilex Holding Company partner with?

Scilex Holding Company's notable partners include Oishi Koseido Co., Ltd., Itochu Chemical Frontier Corporation, Romeg Therapeutics, LLC, and others.

What subsidiaries does Scilex Holding Company have?

Scilex Holding Company's subsidiaries include Scilex Pharmaceuticals Inc., Semnur Pharmaceuticals, Inc., Scilex Bio, Inc..

Where is Scilex Holding Company headquartered?

Scilex Holding Company is headquartered in United States of America and employs approximately 105 people. It has been publicly traded since 2022.

Scilex Holding Company

SCLX

Scilex Holding Company is a revenue-generating biopharmaceutical firm specializing in the acquisition, development, and commercialization of non-opioid pain management products.

Market cap

$49.44M-32.3%

Revenue$33.9M-33.2%

Net income-$393.6M-428%

EPS (diluted)-$40.47-115%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 20, 2026

Revenue$8.6MMiss by $6.4M EPS-$4.76Miss by $4.42

Read the full report

Next report

Sep 2, 2026 (in a month)

Revenue estimate$16.0M

EPS estimate-$0.18

Financials

Q1 2026

Income statement

See full

Revenue$8.6M+72.1%

Gross profit$4.2M+15.1%

Operating income-$32.2M-15.3%

Net income-$45.7M-75.0%

EPS (diluted)-$6.28-178%

Balance sheet

See full

Cash & equivalents$3.4M-42.2%

Total debt$95.4M+130%

Total equity-$249.2M-17.8%

Total assets$293.6M+272%

Cash flow

See full

Operating cash flow-$1.1M-118%

Valuation & ratios

Valuation

See full

Market cap$49.44M-32.3%

Enterprise value$141.44M+12.9%

P/S1.5×-0.5×

Profitability

See full

Gross margin59.7%-12.3pp

Operating margin-1,034.4%-1,313pp

Net margin-1,162.4%-1,359pp

Returns & leverage

See full

Current ratio0.1×0.0×

Competitors

By market cap

Viatris$20.5B+89.0%

Ultragenyx Pharmaceutical$2.6B+1.5%

Collegium Pharmaceutical, Inc.$1.2B+14.3%

Zevra Therapeutics, Inc.$574.0M-2.9%

PTH

Pelthos Therapeutics Inc.$95.9M+42.4%

Scilex Holding Company$49.4M-43.6%

SCN

Scienture Holdings, Inc.$14.9M-43.4%

Soligenix, Inc.$5.4M+28.4%

By revenue growth

Zevra Therapeutics, Inc.+201%

Collegium Pharmaceutical, Inc.+19.9%

Ultragenyx Pharmaceutical+13.5%

Viatris+1.6%

Scilex Holding Company-33.2%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Collegium Pharmaceutical, Inc.9.41%+2.8pp

Viatris-2.04%+24.4pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

PTH

Pelthos Therapeutics Inc.-186.23%—

Scilex Holding Company-1,162.43%-1,015pp

Profile

Scilex Holding Company is a revenue-generating biopharmaceutical firm specializing in the acquisition, development, and commercialization of non-opioid pain management products. The company focuses on addressing high unmet needs in acute and chronic pain through innovative delivery systems and non-addictive therapies. Their mission is to provide safer alternatives to traditional opioid treatments for conditions such as postherpetic neuralgia, migraines, and gout.

Competitive position

Scilex positions itself as a leader in non-opioid pain management by leveraging proprietary adhesion and delivery technologies that offer superior performance over generic and branded hydrogel patches.

GeographiesUnited States, Canada, Global

Customer segmentsHealthcare Providers, Wholesale Distributors, Pharmacies, Payors

Business modelProduct-based, Research and Development, Licensing, Asset Management

SuppliersContract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Third-party logistics providers, Cryptocurrency custodians

CustomersPharmaceutical wholesalers, Retail pharmacy chains, Managed care payors, Hospitals and pain clinics

CountryUnited States of America

Listed2022

Employees105.0

CEOHenry H. Ji

SectorHealthcare

IndustryDrug Manufacturers - General

Websitescilexholding.com

FilingsSEC EDGAR

Ask your AI about Scilex Holding Company.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Scilex Holding Company's market cap?: Scilex Holding Company (SCLX) has a market capitalization of $49.4M and trades on NASDAQ.
What is Scilex Holding Company's revenue and profitability?: Scilex Holding Company generated $33.9M in trailing twelve-month revenue with a net loss of $393.6M, representing a net margin of -1162.4%. Gross margin stands at 59.7%. These figures are based on the Q1 2026 filing.
Who are Scilex Holding Company's competitors?: Scilex Holding Company's key competitors include Viatris Inc., Collegium Pharmaceutical, Inc., Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Scilex Holding Company partner with?: Scilex Holding Company's notable partners include Oishi Koseido Co., Ltd., Itochu Chemical Frontier Corporation, Romeg Therapeutics, LLC, and others.
What subsidiaries does Scilex Holding Company have?: Scilex Holding Company's subsidiaries include Scilex Pharmaceuticals Inc., Semnur Pharmaceuticals, Inc., Scilex Bio, Inc..
Where is Scilex Holding Company headquartered?: Scilex Holding Company is headquartered in United States of America and employs approximately 105 people. It has been publicly traded since 2022.